Boston Life Sciences, Inc. Product Pipeline
(information and links below last updated: Winter 2005)
© Boston Life Sciences. 2006. All rights reserved. Important Legal Notice
ALTROPANE® |
123 I-Based imaging agent for the early diagnosis of Parkinson's Disease (PD). |
POET-1 Phase III trial ended early to evaluate full data set. Results expected in Q3 2006. |
ALTROPANE® |
123 I-Based imaging agent for the objective diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) |
Phase II |
Inosine |
Nerve growth factors for the treatment of stroke and spinal cord injury. |
Pre-Clinical |
FLUORATEC |
Technetium (99Tc) based imaging agent for the diagnosis of PD and ADHD |
Pre-Clinical |
O-1369 |
Novel DAT Blocker for the treatment of Parkinson's Disease |
Pre-Clinical |